Scotland's Life Sciences Sector Can Benefit From Big Pharma's Pickle Pharmaceuticals
Sunday Herald › December 12, 2006
Linked as:
Summary
THE failure of Pfizer's promising Torcetrapib pill last week provided a stark reminder of the pickle in which many large pharmaceutical companies find themselves.
Spending dollars1 billion only to see a drug falter at the final stages of human trials is a major blow from the point of view of investors and shareholders and an occurrence that Big Pharma would rather avoid.See the full content of this document
Extract
Scotland's Life Sciences Sector Can Benefit From Big Pharma's Pickle Pharmaceuticals
And yet, escalating drug development costs and the difficulty in predicting how new medicines will react in humans mean t...
See the full content of this document
Sponsored links
